대한갑상선학회 갑상선분화암 진료권고안; Part I. 갑상선분화암의 초기치료 - 제6장 갑상선분화암의 갑상선절제술 후 방사성요오드 치료 2024

키워드

참고문헌 (94)

1. Avram AM, "Preablation 131-I scans with SPECT", CT in postoperative thyroid cancer patients : what is the impact on staging?, 2013, pp.98(3), 1163~1171
2. Chen MK, "The utility of I-123 pretherapy scan in I-131radioiodine therapy for thyroid cancer", Thyroid, 22(3), pp.304~309 (2012)
3. Van Nostrand D, "The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer", Thyroid, 19(8), pp.849~855 (2009)
4. Lee SW, "SPECT", CT in the treatment of differentiated thyroid cancer, 2017, pp.51(4), 297~303
5. Song H, "Diagnostic 123I whole body scan prior to ablation of thyroid remnant in patients with papillary thyroid cancer : implications for clinical management", Clin Nucl Med, 43(10), pp.705~709 (2018)
6. de Koster EJ, "Radioiodine in differentiated thyroid carcinoma : do we need diagnostic pre-ablation iodine-123scintigraphy to optimize treatment?", Diagnostics(Basel), 11(3), pp.553~ (2021)
7. Gulec SA, "A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on current diagnostic and theranostic approaches in the management of thyroid cancer", Thyroid, 31(7), pp.1009~1019 (2021)
8. Wong KK, "Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT", CT, 2010, pp.195(3), 730~736
9. Chong A, "Clinical implications of adding SPECT", CT to radioiodine whole-body scan in patients with differentiated thyroid cancer : a systematic review and meta-analysis, 2024, pp.49(3), 215~225
10. Avram AM, "Preablation 131-I scans with SPECT", CT contribute to thyroid cancer risk stratification and 131-I therapy planning, 2015, pp.100(5), 1895~1902
11. Gerard SK, "I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours", Clin Nucl Med, 27(1), pp.1~8 (2002)
12. Tuttle RM, "Controversies, consensus, and collaboration in the use of(131)I therapy in differentiated thyroid cancer : a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association", Thyroid, 29(4), pp.461~470 (2019)
13. Schvartz C, "Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients", J Clin Endocrinol Metab, 97(5), pp.1526~1535 (2012)
14. Jonklaas J, "Outcomes of patients with differentiated thyroid carcinoma following initial therapy", Thyroid, 16(12), pp.1229~1242 (2006)
15. Jonklaas J, "Radioiodine therapy in patients with stage I differentiated thyroid cancer", Thyroid, 20(12), pp.1423~1424 (2010)
16. Leboulleux S, "Thyroidectomy without radioiodine in patients with low-risk thyroid cancer", N Engl J Med, 386(10), pp.923~932 (2022)
17. Mallick U, "Iodine or not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo", Clin Oncol (R Coll Radiol), 24(3), pp.159~161 (2012)
18. Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
19. Hindie E, "Thyroid cancer recurrence in the HiLo trial", Lancet Diabetes Endocrinol, 7(4), pp.252~ (2019)
20. Verburg FA, "Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 43(6), pp.1001~1005 (2016)
21. Luster M, "European perspective on 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : Proceedings of an Interactive International Symposium", Thyroid, 29(1), pp.7~26 (2019)
22. Avram AM, "SNMMI procedure standard", EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer : abbreviated version, 2022, pp.63(6), 15N~35N
23. Petranović Ovčariček P, "SNMMI", EANM practice guideline vs. ETA consensus statement : differences and similarities in approaching differentiated thyroid cancer management-the EANM perspective, 2022, pp.49(12), 3959~3963
24. Schmidt M, "Individualized treatment of differentiated thyroid cancer : the value of surgery in combination with radioiodine imaging and therapy-a German position paper from Surgery and Nuclear Medicine", Nuklearmedizin, 61(2), pp.87~96 (2022)
25. Kazaure HS, "Aggressive variants of papillary thyroid cancer : incidence, characteristics and predictors of survival among 43, 738 patients", Ann Surg Oncol, 19(6), pp.1874~1880 (2012)
26. Ruel E, "Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer", J Clin Endocrinol Metab, 100(4), pp.1529~1536 (2015)
27. Sawka AM, "An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer", Endocrinol Metab Clin North Am, 37(2), pp.457~480 (2008)
28. Lamartina L, "Low-risk differentiated thyroid cancer and radioiodine remnant ablation : a systematic review of the literature", J Clin Endocrinol Metab, 100(5), pp.1748~1761 (2015)
29. Klain M, "Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence : a systematic review and a meta-analysis", Eur J Nucl Med Mol Imaging, 48(13), pp.4437~4444 (2021)
30. Chow SM, "Local and regional control in patients with papillary thyroid carcinoma : specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition", Endocr Relat Cancer, 13(4), pp.1159~1172 (2006)
31. Lee EK, "A phase II multi-center, non-randomized, parallel group, noninferiority study to compare the efficacy of no radioactive iodine remnant ablation to remnant ablation treatment in low-to intermediate-risk of papillary thyroid cancer : the MOREthyroid trial protocol", Endocrinol Metab(Seoul), 35(3), pp.571~577 (2020)
32. Pacini F, "2022 ETA consensus statement : what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?", Eur Thyroid J, 11(1), pp.e210046~ (2022)
33. Podnos YD, "Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope", J Surg Oncol, 96(1), pp.3~7 (2007)
34. Filetti S, "Thyroid cancer : ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 30(12), pp.1856~1883 (2019)
35. Durante C, "Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy", J Clin Endocrinol Metab, 91(8), pp.2892~2899 (2006)
36. Mallick U, "Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer", N Engl J Med, 366(18), pp.1674~1685 (2012)
37. Schlumberger M, "Strategies of radioiodine ablation in patients with low-risk thyroid cancer", N Engl J Med, 366(18), pp.1663~1673 (2012)
38. Dehbi HM, "Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer(HiLo) : long-term results of an open-label, non-inferiority randomised controlled trial", Lancet Diabetes Endocrinol, 7(1), pp.44~51 (2019)
39. Schlumberger M, "Outcome after ablation in patients with low-risk thyroid cancer(ESTIMABL1) : 5-year follow-up results of a randomised, phase 3, equivalence trial", Lancet Diabetes Endocrinol, 6(8), pp.618~626 (2018)
40. James DL, "Radioiodine remnant ablation for differentiated thyroid cancer : a systematic review and meta-analysis", JAMA Otolaryngol Head Neck Surg, 147(6), pp.544~552 (2021)
41. Han JM, "Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension", Thyroid, 24(5), pp.820~825 (2014)
42. Wang C, "Low activity versus high activity : noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension", Nucl Med Commun, 38(5), pp.366~371 (2017)
43. Ha S, "Clinical outcome of remnant thyroid ablation with low dose radioiodine in Korean patients with low to intermediate-risk thyroid cancer", J Korean Med Sci, 30(7), pp.876~881 (2015)
44. Sohn SY, "Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer", Thyroid, 23(6), pp.741~747 (2013)
45. Jeong JH, "Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediaterisk differentiated thyroid cancer", Nucl Med Commun, 38(3), pp.228~233 (2017)
46. Kwon SY, "Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer : a multicenter retrospective cohort study", Eur J Nucl Med Mol Imaging, 47(3), pp.561~571 (2020)
47. Blumhardt R, "Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer : a narrative review", Endocr Relat Cancer, 21(6), pp.R473~R484 (2014)
48. "NCCN clinical practice guidelines in oncology (NCCN Guidelines®): Thyroid carcinoma. version 1" (2024)[URL]
49. Jeong SY, "Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy", Sci Rep, 9(1), pp.5570~ (2019)
50. Deandreis D, "Comparison of empiric versus whole-body", -blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer, 2017, pp.58(5), 717~722
51. Park S, "Comparison of recombinant human thyroid-stimulating hormone and thyroid hormone withdrawal for 131 I therapy in patients with intermediate-to high-risk thyroid cancer : a systematic review and meta-analysis", Clin Nucl Med, 49(3), pp.e96~e104 (2024)
52. Borget I, "Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer : results from the randomized phase III ESTIMABL trial", J Clin Oncol, 33(26), pp.2885~2892 (2015)
53. Lee J, "Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma", Thyroid, 20(2), pp.173~179 (2010)
54. Coerts HI, "Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer : state of knowledge and current controversies", Eur J Endocrinol, 188(2), pp.lvad006~ (2023)
55. Robbins RJ, "Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine", Thyroid, 16(11), pp.1121~1130 (2006)
56. Hershman JM, "Serum thyrotropin(TSH)levels after thyroid ablation compared with TSH levels after exogenous bovine TSH : implications for 131-I treatment of thyroid carcinoma", J Clin Endocrinol Metab, 34(5), pp.814~818 (1972)
57. Hilts SV, "Serial TSH determination after T3withdrawal or thyroidectomy in the therapy of thyroid carcinoma", J Nucl Med, 20(9), pp.928~932 (1979)
58. Martin ND, "Endogenous serum TSH levels and metastatic survey scans in thyroid cancer patients using triiodothyronine withdrawal", Clin Nucl Med, 3(10), pp.401~403 (1978)
59. Goldman JM, "Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer", J Clin Endocrinol Metab, 50(4), pp.734~739 (1980)
60. Schneider AB, "Sequential serum thyroglobulin determinations, 131I scans, and 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer", J Clin Endocrinol Metab, 53(6), pp.1199~1206 (1981)
61. Maxon HR, "Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer", N Engl J Med, 309(16), pp.937~941 (1983)
62. Liel Y, "Preparation for radioactive iodine administration in differentiated thyroid cancer patients", Clin Endocrinol(Oxf), 57(4), pp.523~527 (2002)
63. Sanchez R, "Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the followup of patients with well-differentiated thyroid carcinoma", Arch Med Res, 33(5), pp.478~481 (2002)
64. Grigsby PW, "Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation", J Nucl Med, 45(4), pp.567~570 (2004)
65. Serhal DI, "Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer", J Clin Endocrinol Metab, 89(7), pp.3285~3289 (2004)
66. Leboeuf R, "L-T3 preparation for whole-body scintigraphy : a randomizedcontrolled trial", Clin Endocrinol(Oxf), 67(6), pp.839~844 (2007)
67. Edmonds CJ, "Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine", Br J Radiol, 50(599), pp.799~807 (1977)
68. Fallahi B, "Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma : a large randomized clinical trial", Nucl Med Commun, 33(3), pp.275~282 (2012)
69. Prpic M, "Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid : a comparison of ablation success with different activities of radioiodine(I-131)", Ann Nucl Med, 26(9), pp.744~751 (2012)
70. Karam M, "Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates", Nucl Med Commun, 24(5), pp.489~495 (2003)
71. Vrachimis A, "Endogenous TSH levels at the time of(131)I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality", Eur J Nucl Med Mol Imaging, 43(2), pp.224~231 (2016)
72. Ju N, "TSH >", =30 mU, Eur Thyroid J, pp.2023, 12(4)[DOI]
73. Pluijmen MJ, "Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma", Clin Endocrinol(Oxf), 58(4), pp.428~435 (2003)
74. Maxon HR, "Low iodine diet in I-131 ablation of thyroid remnants", Clin Nucl Med, 8(3), pp.123~126 (1983)
75. Goslings BM, "Proceedings : Effect of a low iodine diet on 131-I therapy in follicular thyroid carcinomata", J Endocrinol, 64(3), pp.30~ (1975)
76. Li JH, "Low iodine diet in differentiated thyroid cancer : a review", Clin Endocrinol(Oxf), 84(1), pp.3~12 (2016)
77. Lee M, "Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas", Thyroid, 24(8), pp.1289~1296 (2014)
78. Herbert G, "Impact of low iodine diets on ablation success in differentiated thyroid cancer : a mixed-methods systematic review and meta-analysis", Clin Endocrinol(Oxf), 97(6), pp.702~729 (2022)
79. Yoo ID, "The success rate of initial(131)I ablation in differentiated thyroid cancer : comparison between less strict and very strict low iodine diets", Nucl Med Mol Imaging, 46(1), pp.34~40 (2012)
80. Ju DL, "The impact of low adherence to the low-iodine diet on the efficacy of the radioactive iodine ablation therapy", Clin Nutr Res, 4(4), pp.267~271 (2015)
81. Park JT 2nd, "Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine", Thyroid, 14(1), pp.57~63 (2004)
82. Tomoda C, "Reevaluation of stringent low iodine diet in outpatient preparation for radioiodine examination and therapy", Endocr J, 52(2), pp.237~240 (2005)
83. Morris LF, "Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma", Thyroid, 11(8), pp.749~755 (2001)
84. Kim HK, "Daily urine iodine excretion while consuming a low-iodine diet in preparation for radioactive iodine therapy in a high iodine intake area", Clin Endocrinol(Oxf), 75(6), pp.851~856 (2011)
85. Fatourechi V, "Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?", Thyroid, 10(7), pp.573~577 (2000)
86. Sherman SI, "Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma", J Clin Endocrinol Metab, 78(3), pp.629~634 (1994)
87. Souza Rosario PW, "Post I-131 therapy scanning in patients with thyroid carcinoma metastases : an unnecessary cost or a relevant contribution?", Clin Nucl Med, 29(12), pp.795~798 (2004)
88. Ciappuccini R, "Postablation(131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer", Eur J Endocrinol, 164(6), pp.961~969 (2011)
89. Kohlfuerst S, "Posttherapeutic(131)I SPECTCT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen", Eur J Nucl Med Mol Imaging, 36(6), pp.886~893 (2009)
90. Chen L, "Incremental value of 131I SPECT", CT in the management of patients with differentiated thyroid carcinoma, 2008, pp.49(12), 1952~1957
91. Schmidt D, "Five months'follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by(131)ISPECT", CT at the first radioablation, 2010, pp.37(4), 699~705
92. Maruoka Y, "Incremental diagnostic value of SPECT", CT with 131I scintigraphy after radioiodine therapy in patients with welldifferentiated thyroid carcinoma, 2012, pp.265(3), 902~909
93. Grewal RK, "The effect of posttherapy 131I SPECT", CT on risk classification and management of patients with differentiated thyroid cancer, 2010, pp.51(9), 1361~1367
94. Jeong SY, "Clinical applications of SPECT", CT after first I-131 ablation in patients with differentiated thyroid cancer, 2014, pp.81(3), 445~451

관련 논문AI추천